IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS
Deferasirox (DSX) is the principal option currently available for iron-chelation-therapy (ICT), principally in the management of myelodysplastic syndromes (MDS), while in primary myelofibrosis (PMF) the expertise is limited. We analyzed our experience in 10 PMF with transfusion-dependent anemia, tre...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
PAGEPress Publications
2014-05-01
|
| Sarja: | Mediterranean Journal of Hematology and Infectious Diseases |
| Aiheet: | |
| Linkit: | http://www.mjhid.org/index.php/mjhid/article/view/1389 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|